---
title: "Pre-market hot trades in US stocks: Tuniu surged 7.52% in pre-market trading, with active capital inflow attracting market attention"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/271338620.md"
description: "Tuniu pre-market up 7.52%; ChowChow Cloud pre-market up 71.01%; Ironwood Pharmaceuticals pre-market up 40.05%; Eason Tech pre-market up 38.59%"
datetime: "2026-01-02T14:06:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271338620.md)
  - [en](https://longbridge.com/en/news/271338620.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271338620.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/271338620.md) | [English](https://longbridge.com/en/news/271338620.md)


# Pre-market hot trades in US stocks: Tuniu surged 7.52% in pre-market trading, with active capital inflow attracting market attention

**Pre-market Hot Trades in US Stocks**

Tuniu, up 7.52% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

**Top Gainers in Pre-market US Stocks**

ChowChow Cloud, up 71.01% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Ironwood Pharmaceuticals is up 40.05% in pre-market. Based on recent key news:

1.  On January 2, Ironwood Pharmaceuticals announced that its 2026 revenue outlook exceeds Wall Street expectations. The net sales of its gastrointestinal disease treatment drug Linzess, co-marketed with AbbVie, are expected to rise, driving the stock price up by 28.5%. Source: Reuters
    
2.  On January 2, Ironwood Pharmaceuticals expects its adjusted EBITDA for 2026 to exceed $300 million, significantly up from last year's level of over $135 million. This financial outlook has boosted market confidence, further driving the stock price up. Source: SEC announcement
    
3.  On January 2, Ironwood Pharmaceuticals plans to initiate a confirmatory trial for short bowel syndrome treatment in the first half of 2026 and will provide trial design details in updates for the fourth quarter of 2025 and the full year. This move demonstrates the company's positive progress in R&D, boosting investor sentiment. Source: WSJ Economic improvement and rising market risk appetite.
    

Eason Tech, up 38.59% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation

### 相關股票

- [Tuniu (TOUR.US)](https://longbridge.com/zh-HK/quote/TOUR.US.md)

## 相關資訊與研究

- [China's Tuniu Q4 revenue rises on package tours strength](https://longbridge.com/zh-HK/news/277917064.md)
- [Hutchmed to Withdraw Cancer Drug in China](https://longbridge.com/zh-HK/news/278378041.md)
- [BlackRock Reports 10.6% Capital and 11.8% Voting Stake in Qiagen](https://longbridge.com/zh-HK/news/279096031.md)
- [Genedrive shareholders back fundraising as company expands pharmacogenetic footprint](https://longbridge.com/zh-HK/news/278383713.md)
- [ANI Pharmaceuticals touts rare-disease pivot at Barclays, guides 2026 revenue above $1B](https://longbridge.com/zh-HK/news/278816969.md)